23andMe Develops First Drug Compound Using Consumer Data

Direct-to-consumer genetic testing company 23andMe has developed an antibody aimed at treating inflammatory skin conditions. The DNA testing and research outfit licensed the compound to Barcelona-based pharmaceutical firm Almirall in January, its first such deal for a drug compound developed in-house using consumer data.
Source: JAMA - Category: General Medicine Source Type: research